Eksempler på brug af Mycophenolatmofetil på Dansk og deres oversættelser til Engelsk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Det aktive stof er mycophenolatmofetil.
Mycophenolatmofetil er 2- morpholinoethyl- esteren af MPA.
Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA.CellCept 250 mg kapsler Mycophenolatmofetil.
CellCept 250 mg capsules Mycophenolate mofetil.Mycophenolatmofetil er 2- morpholinoethyl- esteren af mycophenolsyre MPA.
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid MPA.CellCept 500 mg tabletter Mycophenolatmofetil.
CellCept 500 mg tablets Mycophenolate mofetil.Absorptionen af mycophenolatmofetil blev nedsat, når det administreredes sammen med antacida.
Absorption of mycophenolate mofetil was decreased when administered with antacids.Hver kapsel indeholder 250 mg mycophenolatmofetil.
Levende vacciner eller mycophenolatmofetil, fordi deres effektivitet kan blive nedsat ved Noroxin.
Live vaccines or mycophenolate because their effectiveness may be decreased by Noroxin.Myfenax 250 mg kapsler, hårde Mycophenolatmofetil.
Myfenax 250mg hard capsules Mycophenolate mofetil.Mycophenolatmofetil anvendes til at mindske immunsystemets udfordrer for et transplanteret håndtaske.
MYCOPHENOLATE MOFETIL is used to decrease the immune system's defy to a transplanted handbag.Hver tablet indeholder 500 mg mycophenolatmofetil.
Each tablet contains 500 mg mycophenolate mofetil.Uønskede hændelser, som var” sandsynligt relateret” eller” muligt relateret” til mycophenolatmofetil, og som rapporteredes hos de patienter, der blev behandlet med mycophenolatmofetil i de kontrollerede studier med nyre-(2 g data), hjerte- og levertransplanterede patienter er anført i den følgende tabel.
Adverse reactions, probably or possibly related to mycophenolate, reported in of patients treated with mycophenolate in the controlled clinical trials of renal(2 g data), cardiac and hepatic transplant patients are listed in the following table.Hver tablet indeholder 500 mg mycophenolatmofetil.
Each tablet contains 500mg of mycophenolate mofetil.Eftersom mycophenolatmofetil er blevet sat i forbindelse med en øget incidens af bivirkninger i fordøjelsessystemet inklusive sjældne tilfælde af ulceration, blødning og perforation bør Myfenax administreres med forsigtighed til patienter med aktiv alvorlig sygdom i fordøjelsessystemet.
Because mycophenolate has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation, Myfenax should be administered with caution in patients with active serious digestive system disease.Hver tablet indeholder 500 mg mycophenolatmofetil.
The active substance is 500 mg mycophenolate mofetil.I forsøgsmodeller var mycophenolatmofetil ikke tumordannende.
In experimental models, mycophenolate mofetil was not tumourigenic.Mycophenolsyre(MPA) er den aktive metabolit af mycophenolatmofetil.
Mycophenolic acid(MPA) is the active metabolite of mycophenolate mofetil.Patienter, der får immunosuppressiv behandling med kombinationer af lægemidler, inklusive mycophenolatmofetil, har forøget risiko for at udvikle lymfomer og andre maligne lidelser, især i huden se pkt.
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate, are at increased risk of developing lymphomas and other malignancies, particularly of the skin see section 4.4.Myfenax er et lægemiddel, der indeholder det aktive stof mycophenolatmofetil.
Myfenax is a medicine containing the active substance mycophenolate mofetil.To genotoksicitets tests(in vitro muselymfom test og in vivo museknoglemarvs- mikronucleus test)viste, at mycophenolatmofetil potentielt kan forårsage kromosomaberrationer.
Two genotoxicity assays(in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test)showed a potential of mycophenolate mofetil to cause chromosomal aberrations.Der skal iagttages forsigtighed ved samtidig administration pga. muligheden for nedsat effekt af mycophenolatmofetil.
Caution should be used during concomitant administration because of the potential to reduce efficacy of Myfenax.Myfenax 500 filmovertrukne tabletter Mycophenolatmofetil.
Myfenax 500mg film-coated tablets Mycophenolate mofetil.Der skal iagttages forsigtighed med lægemidler, som interfererer med den enterohepatiske cirkulation pga. risikoen for nedsat effekt af mycophenolatmofetil.
Medicinal products that interfere with enterohepatic circulation: caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of Myfenax.Myfenax 500 mg filmovertrukne tabletter Mycophenolatmofetil.
Myfenax 500mg film-coated tablets Mycophenolate mofetil.Det aktive stof i denne medicin hedder mycophenolatmofetil.
The active substance in this medicine is called mycophenolate mofetil.Mycophenolate mofetil Teva 250 mg kapsler, hårde Mycophenolatmofetil.
Den endelige koncentration af opløsningen er 6 mg mycophenolatmofetil per ml.
The final concentration of the solution is 6 mg/ ml mycophenolate mofetil.Ml af den rekonstituerede suspension indeholder 1 g mycophenolatmofetil.
Ml Mycophenolate mofetil Teva 500 filmovertrukne tabletter Mycophenolatmofetil.
